Stockscreener 앱 받기
79.91
2.25%
-1.84
시간 외 거래:
80.72
0.81
+1.01%
전일 마감가:
$81.75
열려 있는:
$82.82
하루 거래량:
1.87M
Relative Volume:
1.35
시가총액:
$8.58B
수익:
$769.10M
순이익/손실:
$46.67M
주가수익비율:
228.31
EPS:
0.35
순현금흐름:
$119.79M
1주 성능:
-4.01%
1개월 성능:
+44.97%
6개월 성능:
-2.00%
1년 성능:
+12.17%
1일 변동 폭
$79.40
$83.30
1주일 범위
$79.40
$85.40
52주 변동 폭
$28.66
$91.00
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
79.91 | 8.58B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan - Stock Titan
Corcept (CORT) director’s entities report 20K-share sale and large holdings - Stock Titan
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome - The Globe and Mail
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corcept Therapeutics Inc (CORT) Institutional Confidence - TradingKey
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome - Business Wire
Corcept Therapeutics Inc (CORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data - GuruFocus
Corcept Therapeutics (CORT) Resubmits Drug Application for Cushi - GuruFocus
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome - Stock Titan
Corcept Therapeutics (CORT) CFO exercises options, sells 40,000 shares in 10b5-1 trades - Stock Titan
Corcept sends relacorilant back to FDA review for Cushing’s syndrome - Stock Titan
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - TMX Newsfile
Charles Schwab (NASDAQ: CORT) files Form 144 listing 20,000 shares - Stock Titan
[144] CORCEPT THERAPEUTICS INC SEC Filing - Stock Titan
Corcept Therapeutics Inc (CORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Legal & General Group Plc Decreases Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Stock On Fire: Up 36% With 12-Day Winning Streak - Trefis
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Stock 12-Day Winning Spree: Stock Climbs 36% - Trefis
Corcept Therapeutics chief development officer sells $1.41m stock By Investing.com - Investing.com Australia
Corcept Therapeutics chief development officer sells $1.41m stock - Investing.com UK
Adrenocortical Carcinoma Market Forecast Signals Robust - openPR.com
Adrenocortical Carcinoma Market Forecast Signals Robust Industry Growth Through 2036 – DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck, Enterome, Bristol-Myers Squibb, UNICANCE - Barchart
Corcept (NASDAQ: CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? - The Motley Fool
Corcept Faces Amended Qui Tam Complaint After DOJ Exit - The Globe and Mail
Corcept Therapeutics president Sean Maduck sells $1.76m in stock - Investing.com UK
11-Day Rally Sends Corcept Therapeutics Stock Up 32% - Trefis
Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree - Trefis
Corcept Therapeutics president Sean Maduck sells $1.76m in stock By Investing.com - Investing.com Australia
Corcept Therapeutics CFO sells $2.8m in company stock - Investing.com
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):